Duloxetine: Clinical Uses, Mechanism of Action and Efficacy


Trevor Norman, Ph.D.
University of Melbourne, Austin Hospital, Heidelberg Victoria, Australia

James S. Olver
University of Melbourne. Deputy Director, General Hospital Psychiatry, Austin Health

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

The class of serotonin and noradrenaline reuptake inhibitors (or SNRIs) were introduced into clinical use as a result of the perceived short-comings of other antidepressant medications. Considerations of efficacy, side effects and tolerability have consistently indicated that there is a clinical need for agents demonstrating improvements in one or more of these domains. Since its introduction in 2007, duloxetine, a representative of the SNRI class, has been shown to be as effective for the treatment of major depression as agents with a longer history of use. In addition, duloxetine has demonstrated efficacy in a number of other conditions and has been extensively investigated in the treatment of generalised anxiety disorder and neuropathic pain states.

The effectiveness of duloxetine in other anxiety states is not as soundly investigated, but the extant evidence is reviewed. Such disorders represent a fertile ground to explore the boundaries of duloxetine therapeutics, with the attended possibility of significant benefits to a broader patient cohort. This volume brings together the clinical evidence for efficacy in these important conditions. Additionally, it explores in detail the pharmacokinetics, metabolism and mechanism of action of the drug. All medications have side effects associated with their use and duloxetine is no exception. A detailed examination of the presentation and incidence of common events associated with the use of the drug as well as rarer treatment emergent adverse events is outlined.

Duloxetine presents itself as a first line treatment of major depressive disorder and as a clinically significant treatment for depressive disorders co-morbid with anxiety and pain states.

Table of Contents

Table of Contents

Chapter 1. Rationale for SNRI Antidepressants

Chapter 2. Pharmacology of Duloxetine

Chapter 3. Duloxetine Pharmacokinetics and Metabolism

Chapter 4. Duloxetine Treatment in Major Depression

Chapter 5. Treatment of Anxiety Disorders with Duloxetine

Chapter 6. Treatment of Pain States

Chapter 7. Adverse Events, Safety and Toxicity

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!